James Felker

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Vaccine Trial for Low Grade Gliomas

Phase 2

Recruiting

Conditions: Low Grade Glioma

First Posted Date: 2015-02-06

Last Posted Date: 2023-11-03

Lead Sponsor: James Felker

Target Recruit Count: 25

Registration Number: NCT02358187

Locations: 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides with Imiquimod

Phase 1

Recruiting

Conditions: Ependymoma

Interventions: Biological: HLA-A2 restricted synthetic tumor antigen
Drug: Imiquimod
Other: enzyme-linked immunosorbent assay
Other: flow cytometry
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis

First Posted Date: 2013-02-20

Last Posted Date: 2024-12-06

Lead Sponsor: James Felker

Target Recruit Count: 24

Registration Number: NCT01795313

Locations: 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas

Phase 1

Completed

Conditions: Newly Diagnosed Pediatric Pontine Glioma
Newly Diagnosed Pediatric High Grade Glioma
Recurrent Pediatric Low Grade Glioma
Recurrent Pediatric High Grade Glioma

Interventions: Biological: HLA-A2 restricted glioma antigen peptides vaccine
Biological: Poly-ICLC

First Posted Date: 2010-05-25

Last Posted Date: 2024-12-06

Lead Sponsor: James Felker

Target Recruit Count: 60

Registration Number: NCT01130077

Locations: 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy